AU Patent

AU2019417158A1 — Domperidone antineurodegenerative combinations and use

Assigned to Chase Therapeutics Corp · Expires 2021-08-12 · 5y expired

What this patent protects

A pharmaceutical combination comprising domperidone, a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and at least one of fluoxetine, zonisamide or a statin, for the treatment of protein misfolding neurodegenerative diseases.

USPTO Abstract

A pharmaceutical combination comprising domperidone, a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and at least one of fluoxetine, zonisamide or a statin, for the treatment of protein misfolding neurodegenerative diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019417158A1
Jurisdiction
AU
Classification
—
Expires
2021-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Chase Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.